CN117320709A - 帕金森病的预防或治疗药 - Google Patents

帕金森病的预防或治疗药 Download PDF

Info

Publication number
CN117320709A
CN117320709A CN202280032414.5A CN202280032414A CN117320709A CN 117320709 A CN117320709 A CN 117320709A CN 202280032414 A CN202280032414 A CN 202280032414A CN 117320709 A CN117320709 A CN 117320709A
Authority
CN
China
Prior art keywords
trisulfide
pharmaceutically acceptable
acceptable salt
compound
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032414.5A
Other languages
English (en)
Chinese (zh)
Inventor
大岛悦男
朝长昌一郎
矶部贵弘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiehe Pharmaceutical Chemical Co ltd
Original Assignee
Xiehe Pharmaceutical Chemical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiehe Pharmaceutical Chemical Co ltd filed Critical Xiehe Pharmaceutical Chemical Co ltd
Publication of CN117320709A publication Critical patent/CN117320709A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D341/00—Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280032414.5A 2021-07-08 2022-07-05 帕金森病的预防或治疗药 Pending CN117320709A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021113378 2021-07-08
JP2021-113378 2021-07-08
PCT/JP2022/026755 WO2023282269A1 (ja) 2021-07-08 2022-07-05 パーキンソン病の予防又は治療薬

Publications (1)

Publication Number Publication Date
CN117320709A true CN117320709A (zh) 2023-12-29

Family

ID=84801700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032414.5A Pending CN117320709A (zh) 2021-07-08 2022-07-05 帕金森病的预防或治疗药

Country Status (5)

Country Link
US (1) US20240293359A1 (https=)
EP (1) EP4342464A4 (https=)
JP (1) JPWO2023282269A1 (https=)
CN (1) CN117320709A (https=)
WO (1) WO2023282269A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12552764B2 (en) 2020-08-27 2026-02-17 Kyowa Pharma Chemical Co., Ltd. Trisulfide compound and clathrate thereof
TW202321270A (zh) * 2021-09-09 2023-06-01 國立大學法人九州大學 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法
WO2025070464A1 (ja) * 2023-09-28 2025-04-03 協和ファーマケミカル株式会社 トリスルフィド化合物を含有する医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043532A1 (ja) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
JP2019511537A (ja) * 2016-04-11 2019-04-25 ユニバーシティ・オブ・キャンベラＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｎｂｅｒｒａ レボドパ、抗酸化剤及び水性担体を含む眼科用組成物
CN111320603A (zh) * 2018-12-13 2020-06-23 江苏同禾药业有限公司 一种硫辛酸工艺杂质的制备方法
CN111699023A (zh) * 2017-12-07 2020-09-22 C·杜克 线粒体靶向、mptp调节以及线粒体反应物质和/或线粒体反应脂质物质的还原
WO2021054149A1 (ja) * 2019-09-18 2021-03-25 国立大学法人 熊本大学 活性イオウ分子種生体内濃度上昇剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP3560947B1 (en) 2016-12-20 2022-08-24 Kyowa Hakko Bio Co., Ltd. Crystal of glutathione trisulfide dihydrate and method for producing same
JP2022074166A (ja) * 2019-01-30 2022-05-18 協和発酵バイオ株式会社 ポリスルフィド化合物を含有する組成物
CN115087635B (zh) 2020-03-31 2024-04-12 协和医药化工股份有限公司 三硫化物化合物或硒代三硫化物化合物的制造方法
JP7842033B2 (ja) * 2020-05-12 2026-04-07 ザ ジェネラル ホスピタル コーポレイション 神経保護におけるグルタチオントリスルフィド（ｇｓｓｓｇ）
US12552764B2 (en) 2020-08-27 2026-02-17 Kyowa Pharma Chemical Co., Ltd. Trisulfide compound and clathrate thereof
JP7650279B2 (ja) 2020-08-27 2025-03-24 協和ファーマケミカル株式会社 トリスルフィド化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043532A1 (ja) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
JP2019511537A (ja) * 2016-04-11 2019-04-25 ユニバーシティ・オブ・キャンベラＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｎｂｅｒｒａ レボドパ、抗酸化剤及び水性担体を含む眼科用組成物
CN111699023A (zh) * 2017-12-07 2020-09-22 C·杜克 线粒体靶向、mptp调节以及线粒体反应物质和/或线粒体反应脂质物质的还原
CN111320603A (zh) * 2018-12-13 2020-06-23 江苏同禾药业有限公司 一种硫辛酸工艺杂质的制备方法
WO2021054149A1 (ja) * 2019-09-18 2021-03-25 国立大学法人 熊本大学 活性イオウ分子種生体内濃度上昇剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMANY A. ABDIN 等: "Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism", NEUROPHARMACOLOGY, vol. 55, no. 8, 1 December 2008 (2008-12-01), pages 1340 - 1346 *
R. MARTONE 等: "Parkinson’s disease as a disorder of the aging", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, vol. 2, no. 4, 1 January 2005 (2005-01-01), pages 299 - 305 *
TIANLI ZHANG等: "Enhanced Cellular Polysulfides Negatively Regulate TLR4 Signaling and Mitigate Lethal Endotoxin Shock", CELL CHEMICAL BIOLOGY, vol. 26, no. 5, 1 May 2019 (2019-05-01), pages 686 *

Also Published As

Publication number Publication date
EP4342464A4 (en) 2025-06-04
US20240293359A1 (en) 2024-09-05
JPWO2023282269A1 (https=) 2023-01-12
WO2023282269A1 (ja) 2023-01-12
EP4342464A1 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
CN117320709A (zh) 帕金森病的预防或治疗药
KR101154351B1 (ko) 암 치료를 위한 벤조퀴논-함유 안사마이신의 유사체
CN115989026A (zh) 三硫化物化合物及其包合物
US10981943B2 (en) Antimicrobial compounds, compositions, and uses thereof
US20240374561A1 (en) Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound
JP2021503441A (ja) Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
WO2014118696A2 (en) Pharmacuetical compositions of rapamycin esters and its derivatives
WO2025131134A1 (zh) 新型艾地苯醌磷酸酯及其盐类化合物、制备方法和用途
EP1954320A2 (en) Compositions comprising lipoxygenase inhibitors and cyclodextrin
WO2013032184A2 (ko) 피라지노-트리아진 유도체를 포함하는 조성물
TW201707707A (zh) 包含吲哚化合物之製劑及其製備方法
US11377468B2 (en) Antimicrobial compounds, compositions, and uses thereof
KR20200059221A (ko) 시포니모드를 포함하는 비경구 제형
EP2303228B1 (en) Fosphenytoin composition
CN103183722A (zh) 一种乙二醛酶ⅰ抑制剂及其制备方法和医药用途
WO2017214680A1 (en) Adamantane compounds
EP4647072A1 (en) Enhancer of physiological activity of hepatocyte growth factor
WO2024122113A1 (ja) 化合物、ナノ粒子、医薬、及びナノ粒子の製造方法
EP4714441A1 (en) Composition for preventing or alleviating hepatic dysfunction
HK40101801A (zh) 基於β取代的β-氨基酸衍生物的化学治疗剂的药物组合物
CN117279642A (zh) 用于预防、抑制、治疗或减少动脉瘤的联合疗法
WO2017219086A1 (en) Anti-ageing compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination